<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03796715</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R76/2018</org_study_id>
    <nct_id>NCT03796715</nct_id>
  </id_info>
  <brief_title>Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients</brief_title>
  <official_title>Comparison of Red Cell Distribution Width Versus Presepsin (Soluble CD14) for Prognosis Assessment in Sepsis Patients Admitted to the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting&#xD;
      its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher&#xD;
      Prsepsin levels compared to those with SIRS. In addition the increase in Prsepsin levels&#xD;
      correlates well with sepsis severity. Red cell distribution width variations are increased in&#xD;
      a variety of medical conditions such as congestive heart failure, acute myocardial&#xD;
      infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a&#xD;
      predictor of mortality in the general population. we aim to compare between Presepsin&#xD;
      (soluble CD14) and RDW as prognostic markers in critically-ill patients with sepsis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">December 24, 2018</completion_date>
  <primary_completion_date type="Actual">November 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality during intensive care unit stay</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for readmission to ICU</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory support duration</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who need renal replacement therapy</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who need inotropic or vasopressor support</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirements (blood and blood products)</measure>
    <time_frame>assessed up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Red Cell Distribution Width (RDW)</arm_group_label>
    <description>RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presepsin (sCD14-ST)</arm_group_label>
    <description>Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Red Cell Distribution Width (RDW)</intervention_name>
    <description>A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.</description>
    <arm_group_label>Red Cell Distribution Width (RDW)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Presepsin (sCD14-ST)</intervention_name>
    <description>: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.</description>
    <arm_group_label>Presepsin (sCD14-ST)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the general ICU with sepsis or septic shock of both sexes between 18&#xD;
        and 65 years of age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 65 years.&#xD;
&#xD;
          -  Appropriate clinical data to enable classification into sepsis or SIRS according to&#xD;
             Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).&#xD;
&#xD;
          -  Written informed consent by the patient or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Hematologic diseases&#xD;
&#xD;
          -  Neutropenia&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Chemotherapy during the previous 90 days.&#xD;
&#xD;
          -  Patients using antibiotics at presentation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elsayed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2019</study_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Elsayed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>presepsin</keyword>
  <keyword>red cell distribution width</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

